Johnson & Johnson (NYSE:JNJ) continues to stand out as a dividend stock for investors who value dependable income and a long track record of growth. In April 2026, the company raised its dividend by 3.1%, bringing the quarterly payment to $1.34, or $5.36 a year. It was the company’s 64th consecutive year of dividend increases, keeping J&J firmly in the Dividend Kings group.
A Well-Covered Dividend
The dividend looks well supported by the size and diversity of Johnson & Johnson (NYSE:JNJ)’s earnings base. The company brought in $25.3 billion in revenue during the second quarter of 2026, a 6.6% increase from the same period last year. Adjusted EPS climbed 4.7% to $2.90, while free cash flow jumped to about $8.7 billion from $6.2 billion a year earlier. Management also raised its full-year outlook, calling for about $101.1 billion in 2026 sales and adjusted EPS of $11.68.
Against that backdrop, the $5.36 annual dividend looks reasonable. Using management’s adjusted EPS guidance, the payout ratio comes to roughly 46%. J&J is therefore retaining more than half of its adjusted earnings, leaving room for research and development, acquisitions, debt reduction, and future dividend increases.
Cash flow also gives dividend investors some comfort. J&J generated approximately $19.7 billion in free cash flow in 2025, which provided ample coverage for its dividend payments.
The Bull Case for J&J’s Dividend
The strongest part of the bull case is the resilience of the underlying business. Johnson & Johnson (NYSE:JNJ) has two major businesses, Innovative Medicine and MedTech. That gives the company exposure to several parts of healthcare rather than tying its fortunes to one product or treatment area. J&J says more than 75% of its sales come from businesses that hold a No. 1 or No. 2 position in their global markets.
That breadth matters when individual drugs run into patent expirations, biosimilar competition, or pricing pressure. Older products will eventually lose momentum, but the size of J&J’s portfolio gives the company more opportunities to replace that revenue with new medicines and medical technologies.
Johnson & Johnson (NYSE:JNJ) is already showing signs that it can replenish its portfolio. During the first quarter, the company received FDA approval for ICOTYDE, an oral peptide for plaque psoriasis and the first targeted oral peptide of its kind. It could become another source of growth for the pharmaceutical business over time.
ICOTYDE is only part of the story. J&J is also working on treatments across oncology, immunology, neuroscience, cardiovascular disease, surgery, and vision. During the second quarter, the company pointed to progress with TREMFYA, RYBREVANT FASPRO, TALVEY, and DARZALEX FASPRO.
This is important for the dividend. Johnson & Johnson (NYSE:JNJ) does not need every medicine to remain a blockbuster indefinitely. It needs a steady flow of new products that can replace older ones and keep earnings moving higher over time. The business also offers some protection when the economy weakens. Healthcare needs do not simply go away during a recession. Patients still need medicines, surgeries, medical devices, and other treatments. Insurance coverage also means demand for many J&J products is less tied to discretionary consumer spending than it is for many other businesses. For investors who put stability first, that is an important advantage.
Dividend Growth Could Remain Moderate
Johnson & Johnson (NYSE:JNJ)’s dividend is unlikely to grow at the same pace it did decades ago. The latest 3.1% increase was already below the 4.8% increase announced in 2025. For investors focused on long-term income, that does not have to be a major concern.
For a company of J&J’s size and maturity, a steady increase supported by earnings and free cash flow may be preferable to a larger payout hike that puts pressure on the balance sheet. There appears to be enough room to keep raising the dividend while still putting money toward growth. The 2026 outlook also supports that view, with adjusted EPS expected to reach $11.68.
Conclusion
Johnson & Johnson (NYSE:JNJ)’s dividend looks well positioned for the long term. A 64-year streak is impressive, but the bigger point is that the business is still producing the earnings and cash flow needed to fund the payout.
There are still challenges, particularly biosimilar competition and pressure on drug pricing. So far, though, they have not stopped the broader business from growing. Revenue is higher, free cash flow remains strong, and management has raised its outlook for 2026.
The pharmaceutical pipeline adds another layer to the bull case. Products such as ICOTYDE, along with treatments being developed across several major areas, give J&J more ways to offset declines from older medicines. For dividend investors, J&J is more about reliability than spectacular dividend growth. The roughly 46% adjusted earnings payout ratio, solid free cash flow, diversified healthcare operations, and 64-year dividend growth streak give the company room to continue rewarding shareholders. Dividend growth may remain modest, but for a business with J&J’s financial strength and stability, that looks like a reasonable trade-off.
While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Badger Meter is Quietly Building a Strong Dividend Growth Record and Kimberly-Clark (KMB): An Overlooked Dividend King Income Investors Should Know
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center